Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Total Liabilities (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Total Liabilities for 9 consecutive years, with $438051.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 95.61% year-over-year to $438051.0, compared with a TTM value of $438051.0 through Oct 2025, up 95.61%, and an annual FY2025 reading of $347567.0, up 153.85% over the prior year.
  • Total Liabilities was $438051.0 for Q4 2025 at VitaNova Life Sciences, up from $379975.0 in the prior quarter.
  • Across five years, Total Liabilities topped out at $438051.0 in Q4 2025 and bottomed at $32107.0 in Q3 2021.
  • Average Total Liabilities over 5 years is $149154.6, with a median of $92895.5 recorded in 2023.
  • The sharpest move saw Total Liabilities plummeted 76.01% in 2021, then skyrocketed 153.85% in 2025.
  • Year by year, Total Liabilities stood at $48791.0 in 2021, then surged by 34.13% to $65443.0 in 2022, then soared by 40.91% to $92217.0 in 2023, then skyrocketed by 142.84% to $223938.0 in 2024, then soared by 95.61% to $438051.0 in 2025.
  • Business Quant data shows Total Liabilities for YJGJ at $438051.0 in Q4 2025, $379975.0 in Q3 2025, and $347567.0 in Q2 2025.